デフォルト表紙
市場調査レポート
商品コード
1377950

移植用HLAタイピング市場:製品・サービス、技術、移植タイプ、用途、エンドユーザー別-2023-2030年世界予測

HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
移植用HLAタイピング市場:製品・サービス、技術、移植タイプ、用途、エンドユーザー別-2023-2030年世界予測
出版日: 2023年11月03日
発行: 360iResearch
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

移植用HLAタイピング市場は、2022年の9億1,900万米ドルから2030年には18億3,658万米ドルに達すると予測され、予測期間中のCAGRは9.04%です。

移植用HLAタイピングの世界市場

主な市場の統計
基準年[2022] 9億1,900万米ドル
予測年[2023] 9億9,831万米ドル
予測年[2030] 18億3,658万米ドル
CAGR(%) 9.04%
移植用HLAタイピング Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは移植用HLAタイピング市場の評価に不可欠なツールです。事業戦略と製品満足度に関連する主要指標を分析し、ベンダーを包括的に評価します。これにより、ユーザーは特定のニーズに合わせた情報に基づいた意思決定を行うことができます。高度な分析により、ベンダーは4つの象限に分類され、それぞれ成功のレベルが異なります:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。この洞察に満ちたフレームワークにより、意思決定者は自信を持って市場をナビゲートすることができます。

市場シェア分析

市場シェア分析では、ベンダーの市場情勢に関する貴重な洞察を提供します。全体収益、顧客ベース、その他の主要指標への影響を評価することで、企業の業績と直面する競合環境を包括的に理解することができます。この分析では、調査期間中の市場シェア獲得、断片化、優位性、業界再編などの競合レベルも明らかにします。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業の市場力学と製品に関する包括的な情報を提供します。

2.市場の開拓度:新興市場と成熟市場セグメントへの浸透度を詳細に分析し、有利なビジネスチャンスを浮き彫りにします。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報。

4.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関するインテリジェントな洞察。

本レポートは、以下のような主要な質問に対応しています:

1.移植用HLAタイピング市場の市場規模および予測は?

2.移植用HLAタイピング市場で最も高い投資ポテンシャルを持つ製品、セグメント、用途、分野は?

3.移植用HLAタイピング市場における競争戦略の窓とは?

4.移植用HLAタイピング市場の最新技術動向と規制の枠組みは?

5.移植用HLAタイピング市場における主要ベンダーの市場シェアは?

6.移植用HLAタイピング市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 骨髄、臓器、血液の移植プロセスの発生率の上昇
      • 移植片拒絶反応を減らすための個別化医療におけるHLAタイピングの採用
    • 抑制要因
      • 償還の欠如と不適切な保険契約
    • 機会
      • 移植診断およびHLAタイピング法の分野における技術の進歩
      • HLAタイピングを補完する免疫抑制療法を好む
    • 課題
      • HLAタイピングの不正確さに関する懸念
  • 市場セグメンテーション分析
    • 技術:高い特異性と再現性を備えた分子アッセイ技術の採用
    • 製品とサービス:データの解釈と研究室のワークフローの管理を容易にするソフトウェアとサービスの優先順位
    • 移植の種類:白血病、リンパ腫、骨髄腫、免疫系疾患に対する幹細胞移植療法の利用が増加
    • 応用:臓器移植の診断用途におけるHLAタイピングの使用
    • エンドユーザー:高スループット機能と拡張性を実現する独立したリファレンスラボでの高い普及率
  • 市場動向分析
    • 先進的なヘルスケアの研究開発と確立された市場ベンダーの存在により、南北アメリカにおけるHLAタイピングの拡大が促進されます
    • APACにおける移植用HLAタイピング市場をダイナミックに拡大し、移植のための改善されたヘルスケアインフラを提供するための先進技術の導入に重点を置く
    • EMEAで有利な市場情勢を作り出すために、移植手順と高品質のHLAタイピングの商業化に対する政府支援のニーズが高まっている
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 移植用HLAタイピング市場製品&サービス別

  • 機器
  • 試薬と消耗品
  • ソフトウェアとサービス

第7章 移植用HLAタイピング市場:技術別

  • 分子アッセイ技術
    • PCRベースの分子アッセイ
      • リアルタイムPCR
      • 配列特異的オリゴヌクレオチド PCR
      • 配列特異的プライマーPCR
    • シーケンスベースの分子アッセイ
      • 次世代シーケンス
      • サンガー配列決定
  • 非分子アッセイ技術

第8章 移植用HLAタイピング市場移植タイプ別

  • 臓器移植
  • 幹細胞移植
  • 組織移植

第9章 移植用HLAタイピング市場:用途別

  • 診断アプリケーション
    • 抗体スクリーニング
    • キメリズム監視
  • 調査用途

第10章 移植用HLAタイピング市場:エンドユーザー別

  • 臨床検査機関および調査機関
  • 病院と移植センター
  • 独立した基準研究所

第11章 南北アメリカの移植用HLAタイピング市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の移植用HLAタイピング市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの移植用HLAタイピング市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別
    • 合併・買収
    • 契約、コラボレーション、パートナーシップ
    • 新製品発売と機能強化
    • 投資、資金調達

第15章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Agilent Technologies, Inc.
    • BAG Diagnostics GmbH
    • Becton, Dickinson, and Company
    • BGI Genomics Co.,Ltd.
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • CapitalBio Technology Co., Ltd.
    • CareDx, Inc.
    • CeGaT GmbH
    • Chugai Pharmaceutical Co., Ltd.
    • Creative Biolabs, Inc.
    • DiaSorin S.p.A.
    • Eurofins Scientific SE
    • F. Hoffman-La Roche AG
    • Fujirebio, Inc. by H.U. Group Holdings, Inc.
    • Garuda Therapeutics
    • GenDx by Eurobio Scientific Group
    • HEALIOS K.K.
    • Hologic, Inc.
    • Illumina, Inc.
    • Immatics N.V.
    • Immucor, Inc. by Werfen, S.A.
    • ImmunOs Therapeutics AG
    • Invectys Inc.
    • Laboratory Corporation of America Holdings
    • Lonza Group Ltd.
    • Merck KGaA
    • NeoGenomics Laboratories, Inc.
    • OraSure Technologies, Inc.
    • Oxford Nanopore Technologies PLC
    • Pure MHC, LLC
    • Pure Protein, LLC
    • QIAGEN N.V.
    • STEMCELL Technologies Inc.
    • T-Cure Bioscience Inc.
    • Takara Bio Inc.
    • TBG Diagnostics Ltd.
    • TCRツイTherapeutics by Adaptimmune Therapeutics PLC
    • Thermo Fisher Scientific, Inc.
  • 主要な製品ポートフォリオ

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
  • FIGURE 7. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2030 (%)
  • FIGURE 8. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
  • FIGURE 10. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2022 VS 2030 (%)
  • FIGURE 12. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 14. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 16. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 18. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 20. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 6. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 10. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 12. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 14. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 19. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 29. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 230. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 248. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 257. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 266. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 275. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 284. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 293. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 302. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)

TABL

目次
Product Code: MRR-3D2FD205B890

The HLA Typing for Transplant Market is projected to reach USD 1,836.58 million by 2030 from USD 919.00 million in 2022, at a CAGR of 9.04% during the forecast period.

Global HLA Typing for Transplant Market

KEY MARKET STATISTICS
Base Year [2022] USD 919.00 million
Estimated Year [2023] USD 998.31 million
Forecast Year [2030] USD 1,836.58 million
CAGR (%) 9.04%
HLA Typing for Transplant Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the HLA Typing for Transplant Market.

Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services. The Reagents & Consumables commanded largest market share of 51.23% in 2022, followed by Instruments.

Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing. The Molecular Assay Technologies commanded largest market share of 57.88% in 2022, followed by Non-Molecular Assay Technologies.

Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation. The Tissue Transplantation commanded largest market share of 36.12% in 2022, followed by Organ Transplantation.

Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring. The Research Applications commanded largest market share of 63.23% in 2022, followed by Diagnostic Applications.

Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories. The Independent Reference Laboratories commanded largest market share of 52.12% in 2022, followed by Clinical Laboratories & Research Institution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.37% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the HLA Typing for Transplant Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape HLA Typing for Transplant Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR² Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the HLA Typing for Transplant Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the HLA Typing for Transplant Market?

3. What is the competitive strategic window for identifying opportunities in the HLA Typing for Transplant Market?

4. What are the latest technology trends and regulatory frameworks in the HLA Typing for Transplant Market?

5. What is the market share of the leading vendors in the HLA Typing for Transplant Market?

6. Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. HLA Typing for Transplant Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
      • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
      • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
    • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
    • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
    • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
    • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
    • 5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
    • 5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. HLA Typing for Transplant Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

  • 7.1. Introduction
  • 7.2. Molecular Assay Technologies
    • 7.3.1. PCR-Based Molecular Assays
      • 7.3.2.1. Real-Time PCR
      • 7.3.2.2. Sequence-Specific Oligonucleotide-PCR
      • 7.3.2.3. Sequence-Specific Primer-PCR
    • 7.3.2. Sequencing-Based Molecular Assays
      • 7.3.3.1. Next-Generation Sequencing
      • 7.3.3.2. Sanger Sequencing
  • 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

  • 8.1. Introduction
  • 8.2. Organ Transplantation
  • 8.3. Stem Cell Transplantation
  • 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostic Applications
    • 9.3.1. Antibody Screening
    • 9.3.2. Chimerism Monitoring
  • 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories & Research Institution
  • 10.3. Hospitals & Transplant Centers
  • 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player
    • 14.3.1. Merger & Acquisition
      • 14.3.1.1. Eurobio Scientific acquires GenDx for USD 132.3 million
    • 14.3.2. Agreement, Collaboration, & Partnership
      • 14.3.2.1. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
      • 14.3.2.2. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
      • 14.3.2.3. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
      • 14.3.2.4. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension
    • 14.3.3. New Product Launch & Enhancement
      • 14.3.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
      • 14.3.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
      • 14.3.3.3. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
      • 14.3.3.4. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
      • 14.3.3.5. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
    • 14.3.4. Investment & Funding
      • 14.3.4.1. BriaCell receives NCI grant for cancer platform development
      • 14.3.4.2. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. Agilent Technologies, Inc.
    • 15.1.2. BAG Diagnostics GmbH
    • 15.1.3. Becton, Dickinson, and Company
    • 15.1.4. BGI Genomics Co.,Ltd.
    • 15.1.5. Bio-Rad Laboratories, Inc.
    • 15.1.6. Bio-Techne Corporation
    • 15.1.7. CapitalBio Technology Co., Ltd.
    • 15.1.8. CareDx, Inc.
    • 15.1.9. CeGaT GmbH
    • 15.1.10. Chugai Pharmaceutical Co., Ltd.
    • 15.1.11. Creative Biolabs, Inc.
    • 15.1.12. DiaSorin S.p.A.
    • 15.1.13. Eurofins Scientific SE
    • 15.1.14. F. Hoffman-La Roche AG
    • 15.1.15. Fujirebio, Inc. by H.U. Group Holdings, Inc.
    • 15.1.16. Garuda Therapeutics
    • 15.1.17. GenDx by Eurobio Scientific Group
    • 15.1.18. HEALIOS K.K.
    • 15.1.19. Hologic, Inc.
    • 15.1.20. Illumina, Inc.
    • 15.1.21. Immatics N.V.
    • 15.1.22. Immucor, Inc. by Werfen, S.A.
    • 15.1.23. ImmunOs Therapeutics AG
    • 15.1.24. Invectys Inc.
    • 15.1.25. Laboratory Corporation of America Holdings
    • 15.1.26. Lonza Group Ltd.
    • 15.1.27. Merck KGaA
    • 15.1.28. NeoGenomics Laboratories, Inc.
    • 15.1.29. OraSure Technologies, Inc.
    • 15.1.30. Oxford Nanopore Technologies PLC
    • 15.1.31. Pure MHC, LLC
    • 15.1.32. Pure Protein, LLC
    • 15.1.33. QIAGEN N.V.
    • 15.1.34. STEMCELL Technologies Inc.
    • 15.1.35. T-Cure Bioscience Inc.
    • 15.1.36. Takara Bio Inc.
    • 15.1.37. TBG Diagnostics Ltd.
    • 15.1.38. TCR² Therapeutics by Adaptimmune Therapeutics PLC
    • 15.1.39. Thermo Fisher Scientific, Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing